bosis and/or recurrent FL; on the other, recurrent evidence of LA and/or anticardiolipin antibodies (ACL). Objections may be raised to this definition, 5 one of the major problems being the interlaboratory variation in ACL assays and the absence of consensus concerning the normal upper limit of ACL. 6 In our laboratory, we consider the normal upper limit to be 20 GPL units for IgG ACL and 20 MPL units for IgM ACL.
Antiphospholipid-associated obstetrical disorders are not limited to FL. They also include infertility, intrauterine growth retardation, fetal distress, prematurity, 7 and in the mother, preeclampsia 8 and chorea gravidarum. 9 We shall limit ourselves to FL, a term including abortion and fetal death, the limit between these being considered by Branch 1 to be at 20 weeks gestation.
WHEN TO SCREEN FOR ANTIPHOSPHOLIPID ANTIBODIES (APL)?
It is generally considered that screening for APL is unnecessary in asymptomatic gravida 0 or nulliparous women. 11-3 Indeed, LA and ACL positivity are infrequent in these women, being present in less than 4%, and the relationship to the outcome of pregnancy is unclear. However, the findings of Lynch et al. 14 On the other hand, screening becomes cost effective after two, or better, three FL. 13'6-z The problem is that the percent APL positivityin these patients varies widely in different studies. As far as the protein C pathway is concerned, the presence of an acquired deficit of free protein S appears to be established in both APLS secondary 
